Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals and patients are asked to report any suspected adverse reactions via the national reporting schemes: www.famhp.be/en/side_effect (Belgium), https://guichet.public.lu/en/entreprises/sectoriel/sante/medecins/notification-effets-indesirables-medicaments.html (Grand Duchy of Luxembourg) or www.lareb.nl/en (The Netherlands).
Adverse reactions may also be reported directly to the manufacturer of the suspected product. Adverse reactions related to Gilead products may be reported directly to Gilead via email: [email protected].
NL-UNB-0833